Kovo HealthTech Announces Departure of Greg Noble as CEO and Appointment of Brenner Adams as Interim Successor
Kovo HealthTech Announces Departure of Greg Noble as CEO and Appointment of Brenner Adams as Interim Successor
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2024) - Kovo HealthTech Corporation (TSXV: KOVO) ("Kovo" or the "Company") today announced that Mr. Greg Noble has stepped down as Chief Executive Officer and that the Board of Directors has selected Brenner Adams to succeed Mr. Noble as interim CEO.
加拿大卑詩省--(新聞稿-2024年7月9日)-Kovo衛生科技有限公司(TSXV: KOVO) ("Kovo" or the "公司")今日宣佈,Greg Noble先生已經辭去首席執行官職務,董事會選擇Brenner Adams接替Noble擔任臨時首席執行官。
During his tenure, Mr. Noble led the Company's public listing on the TSX Venture Exchange and oversaw several acquisitions and operational efficiencies that grew the company from $1.7M to $10.0M from Fiscal 2019 to Fiscal 2023. Whereas Mr. Noble is departing as CEO, he has signed a long-term contract to provide M&A consulting services for the Company. "KOVO is now well positioned as an acquisition engine for continued growth into the future and I look forward to assisting the team in finding new and valuable RCM targets to purchase," stated Noble.
Noble先生任CEO期間,領導了公司在TSX創業板上市,並監督了多項收購和運營效率,使公司從2019財年的170萬美元增長到2023財年的1000萬美元。雖然Noble先生即將離任CEO,但他已簽訂一份長期合同,爲公司提供併購諮詢服務。「KOVO現在已經做好了成爲未來持續增長的收購引擎的準備,我期待協助團隊尋找新的有價值的RCm目標進行收購。」Noble表示。
Stepping into the CEO position, Brenner Adams is an international executive with a robust background in business development, marketing, and product leadership who significantly impacted the healthcare industry during his tenure as Chief Innovation Officer at Med USA, a Revenue Cycle Management and Credentialing Services company. Additionally, Adams helped launch two successful spinoffs, with one securing public state funding in the process. The Board believes Adams is well-equipped to ensure a seamless transition and continue the company's aggressive growth trajectory.
Brenner Adams擔任CEO一職,是一位具有豐富的商業拓展、市場營銷和產品領導經驗的國際高管,曾在醫療行業擔任過收入循環管理和資格認證服務公司Med USA的首席創新官,產生了重大影響。此外,Adams還幫助推出了兩個成功的子公司,其中一個子公司在過程中獲得了公共國家資金的支持。董事會認爲Adams已經準備好確保無縫過渡,並繼續公司的強勁增長軌跡。
"We extend our gratitude to Greg for his leadership and unwavering dedication during his tenure as CEO and we are confident in Brenner's ability to continue the Company's growth and excellence in all aspects during this transitional period and beyond," said Peter Bak, Kovo's Chairman of the Board.
Kovo董事長Peter Bak表示:"我們感謝Greg在他擔任CEO期間的領導和堅定的奉獻精神,並且我們對Brenner在這個過渡期間和未來所有方面繼續推動公司的增長與卓越能力充滿信心。"
About Kovo HealthTech Corporation
Kovo HealthTech Corporation簡介
Kovo HealthTech Corporation is a growing healthcare technology company that specializes in Billing-as-a-Service offering SaaS-style recurring revenue contracts and software for more than 2250 US healthcare providers. Kovo helps healthcare providers digitally track and manage complex patient care registration, services, billing and payments in a seamless way. Currently, through its clients, Kovo processes over $250 million CAD ($200M USD) in annual billing transactions for more than 3.5 million patients. By offering effective billing practices, Kovo helps healthcare practitioners get paid so they can focus on offering quality care. To learn more about Kovo and to keep up-to-date on Kovo news, visit .
Kovo HealthTech Corporatio是一家快速增長的醫療技術公司,專門提供SaaS樣式的醫療賬單管理服務,爲2250多家美國醫療機構提供軟件服務。Kovo幫助醫療服務提供商以無縫的方式處理和管理繁瑣的患者護理登記、服務、賬單和支付。目前,通過其客戶,Kovo每年爲超過350萬患者處理超過2.5億加元(2億美元)的年度賬單交易。通過提供有效的賬單實踐,Kovo幫助醫療從業者得到報酬,以便他們可以專注於提供優質的醫療保健服務。有關Kovo的更多信息以及Kovo新聞的最新動態,請訪問 。
For more information:
Peter Bak, Board Chair
investors@kovo.co
1-866-558-6777
欲了解更多信息:
Kovo董事長
爲提供公司管理人員有關未來的期望和計劃的信息而提供前瞻性陳述和信息。讀者應該注意,依賴這種陳述和信息可能不適用於其他目的,例如做出投資決策。由於前瞻性陳述和信息涉及未來事件和條件,因其本質而言,它們涉及固有的風險和不確定性。由於多種因素和風險,實際結果可能會與當前預期有所不同。這些因素和風險包括公司在沒有足夠資本的情況下繼續運營的能力,公司籌集進一步資金的能力,公司符合其當前債務義務並能夠無論是否進行債務轉換交易和貸款協議修正來償還其債務,公司有可能滿足擬議中的債務轉換交易和貸款協議的繼續義務,公司有效併成功地開發新機會的能力,未來交易對手的識別失敗以及重組債務交易被完成的可能性以及公司未來不違約的可能性。因此,讀者不應過分依賴本新聞稿中包含的前瞻性陳述和信息。讀者應該注意,上述因素列表並非詳盡無遺。本新聞稿中包含的前瞻性陳述和信息是截至本日的,並沒有承諾公開或修正任何前瞻性陳述或信息,無論是基於新信息,未來事件還是其他原因,除非適用的證券法要求這樣做。本新聞稿中包含的前瞻性陳述或信息明確受到本警示說明的限制。
1-866-558-6777
Forward-Looking Information
前瞻性信息本新聞稿包含包含“前瞻性信息”,涵蓋適用證券法律的範圍。在某些情況下,“前瞻性信息”可以通過使用前瞻性術語諸如“計劃”、“預期”、“預算”、“安排”、“估計”、“前景”、“目標”、“預測”、“投影”、“潛力”、“前景”、“策略”、“意圖”、“預計”、“尋求”、“認爲”、“機會”、“指引”、“目標”或類似的詞語和短語或陳述一定的未來條件、行動、事件或結果“可能”、“可能”、“將”、“應該”、“可能”、“將”、“能夠”或這些詞語和短語的負面版本,“被採取”,“發生”,“繼續”或“實現”,以及其他類似的表達方式。包含前瞻性信息的聲明並不是歷史事實,而是代表管理層對於未來事件或情況的預期、估計和投射。該前瞻性信息與公司未來的財務前景以及預期的事件或結果有關,包括但不限於“財務前景”下的聲明和有關公司財務狀況、財務結果、業務策略、績效、成就、前景、目標、機會、業務計劃和增長策略、公司預算、運營和稅務、影響財務報表的判斷和估計以及D2L Wave的初步分拆。
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to future acquisitions and relative growth of the Company. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Corporation. Although management of the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.
本新聞稿包含前瞻性聲明和前瞻性信息,根據適用的證券法規,它們涉及未來事件或未來表現。除歷史事實陳述外,所有陳述可能均爲前瞻性聲明或信息。特別是,此新聞稿包含前瞻性聲明和信息,涉及未來收購和公司相對增長。前瞻性聲明和信息基於公司管理層做出的某些關鍵預期和假設。儘管公司管理層相信,前瞻性聲明和信息所基於的預期和假設是合理的,但不應過分依賴前瞻性聲明和信息,因爲無法保證它們將被證明是正確的。
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to raise future capital, the Company's ability to meet the terms of its current debt obligations and to repay its indebtedness, the Corporation's ability to efficiently and successfully develop new opportunities, failure to identify future transactional counter-parties . Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
本新聞稿中的前瞻性聲明和信息提供有關公司管理層的當前期望和計劃的信息,涉及未來。讀者應該注意,依賴此類聲明和信息可能不適合其他用途,例如進行投資決策。由於前瞻性聲明和信息涉及未來事件和條件,因其本質具有固有的風險和不確定性,因此實際結果可能與目前預期的結果有所不同。由於許多因素和風險的影響,實際結果可能與當前預期的結果有很大差異。這些因素和風險包括但不限於:公司籌集未來資本的能力;公司能否滿足其當前的債務義務並償還其債務;公司高效、成功地開發新機會,未來交易的交易對手未被發現。因此,讀者不應依賴此新聞稿中包含的前瞻性聲明和信息。讀者應該注意,上述因素列表並非詳盡無遺。本新聞稿中包含的前瞻性聲明和信息是截至本日發佈,且未承諾公開更新或更正任何前瞻性聲明或信息,除非適用的證券法律規定要求這樣做。本新聞稿中包含的前瞻性聲明或信息受到此警示聲明的明確限制。